U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 13271 - 13280 of 13362 results

mixture
Status:
Possibly Marketed Outside US
Source:
NCT00004317: Phase 4 Interventional Recruiting Toxoplasmosis
(2000)
Source URL:

Class:
MIXTURE



Spiramycin, a macrolide antibiotic, has been studied in the United States for the treatment of cryptosporidial diarrhea. Some reports suggest that spiramycin is useful in improving the symptoms of cryptosporidial diarrhea in some patients. It has been used in Europe and Canada for over 20 years to treat bacterial infections. Serious adverse effects from spiramycin are apparently rare, and no drug-associated deaths have been reported. Spiramycin inhibits translocation by binding to bacterial 50S ribosomal subunits with an apparent 1:1 stoichiometry. This antibiotic is a potent inhibitor of the binding to the ribosome of both donor and acceptor substrates. Spiramycin induces rapid breakdown of polyribosomes, an effect which has formerly been interpreted as occurring by normal ribosomal run-off followed by an antibiotic-induced block at or shortly after initiation of a new peptide. However, there is now convincing evidence that spiramycin, and probably all macrolides, act primarily by stimulating the dissociation of peptidyl-tRNA from ribosomes during translocation
mixture
Status:
Possibly Marketed Outside US
Source:
DYNAMYXIN by Pfizer
Source URL:

Class:
MIXTURE



Sulfomyxin is an antibacterial sulfonamide. It is intended for use in chickens and turkeys as an aid in the treatment of disease caused or complicated by E. coli, such as colibacillosis and complicated chronic respiratory disease.
mixture
Status:
Possibly Marketed Outside US

Class:
MIXTURE

mixture
Status:
Possibly Marketed Outside US

Class:
MIXTURE

Butirosin is water-soluble aminoglycosidic antibiotic complex which is active against both Gram-positive and Gram-negative bacteria. Butirosin is less toxic than neomycin and shows a good antibacterial activity, including Pseudomonas aeruginosa, which is resistant to neomycin, ribostamycin and kanamycin.
mixture
Status:
Possibly Marketed Outside US

Class:
MIXTURE

Indenolol hydrochloride is a nonselective beta-adrenoceptor antagonist. It is antihypertensive, antiarrhytmic, antianginal drug. It vasodilated forearm arterioles and this effect was antagonized by beta-blockade, thus demonstrating vascular intrinsic sympathomimetic activity. Indenol is able to inhibit an exercise-induced rise in systolic pressure. Indenolol would be able to decrease myocardial O2 consumption.
Thymopentin is a synthetic pentapeptide which is the active site of the naturally occurring hormone thymopoietin with immunomodulating properties. Thymopentin can specifically promote the differentiation and maturation of thymic T cells and natural killer cells (NK) and enhance the function of T helper cells. thymic can achieve a two-way adjustment to the immune system by increasing the levels of intracellular cyclic adenosine monophosphate, elevating the activity of T cells, and regulating the proportions of T cell subsets. As an immunomodulating agent, Thymopentin is clinically used in the treatments of autoimmune diseases, such as e.g. atopic dermatitis, chronic lymphocytic leukemia, Sezary's syndrome, rheumatoid arthritis, as well as decreased immune competency in elder surgical patients. Due to poor membrane permeability, extensive metabolism in the GI, and extremely short half-life of 30 s, repeated injections or i.v infusions of Thymopentin are necessary which greatly restrict its clinical applications.
Status:
Possibly Marketed Outside US
Source:
NCT01715493: Phase 4 Interventional Completed Chronic Obstructive Pulmonary Disease
(2012)
Source URL:

Class:
PROTEIN

YTTRIUM Y-90 (YTRACIS®, YTTRIGA®) is a radioactive form of the chemical element yttrium. It is used for radiolabelling other medicines. An example of its use is the treatment of some type of tumors, where the radiolabelled medicine carries the radioactivity to the site of a tumor to destroy the tumor cells.
Protein
Status:
Possibly Marketed Outside US

Class:
PROTEIN

Showing 13271 - 13280 of 13362 results